Medical365 tumor tracking software automates RECIST 1.1 lesion measurement, target/non-target tracking & PET Lugano response evaluation in oncology EMR.
Tumor tracking software is a specialized clinical oncology response assessment module. It tracks anatomical target and non-target tumor lesions across longitudinal CT, MRI, and PET scans, automates RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) calculations, determines sum of longest diameters (SLD), and categorizes clinical therapeutic response into Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD).
Addressing high-volume OPD congestion, diagnostic fragmentation, and statutory healthcare regulations.
In clinical oncology, objectively evaluating whether a tumor is shrinking, stable, or progressing under chemotherapy, immunotherapy, or targeted therapy is the definitive criterion for clinical decision-making. Continuing an ineffective cytotoxic regimen wastes valuable time and subjects patients to unnecessary toxicity; conversely, terminating an effective drug prematurely compromises survival.
In conventional practice, tumor response assessment is often subjective and inconsistent. Radiologists and oncologists review CT scans and write narrative impressions such as 'tumor appears slightly smaller' or 'subtle interval progression'. Without systematic measurement of defined baseline target lesions, calculating the exact percentage change in the Sum of Longest Diameters (SLD) according to international RECIST 1.1 standards is virtually impossible during rapid clinical rounds.
Medical365's Tumor Tracking module embeds standardized RECIST 1.1 and iRECIST (immunotherapy response) criteria directly into the oncology chart. Clinicians select baseline target lesions (up to 5 total, maximum 2 per organ), record longest diameters, track non-target lesions, and visualize tumor trajectory graphs that instantly prove whether criteria for partial response (≥30% decrease) or disease progression (≥20% increase) have been met.
Engineered with medical sub-specialists to eliminate manual charting friction and enforce clinical protocol rigor.
Structures baseline selection of up to 5 measurable target lesions (longest diameter for non-nodal lesions ≥10 mm, short axis for lymph nodes ≥15 mm) and qualitative non-target lesions.
Automatically sums target lesion diameters across consecutive imaging scans and computes exact percentage changes from baseline and nadir (smallest previous sum).
Applies RECIST 1.1 mathematical rules to categorize response: Complete Response (CR), Partial Response (PR ≥30% decrease), Progressive Disease (PD ≥20% increase + 5mm absolute increase), or Stable Disease (SD).
Incorporates immune-related response criteria to distinguish pseudoprogression from true progression: unconfirmed progressive disease (iUPD) requiring repeat imaging confirmation versus confirmed progression (iCPD).
Specialized lymphoma tracking utilizing the 5-point Deauville score (1-5) on FDG-PET scans to grade metabolic response following frontline chemotherapy.
Generates intuitive visual spider plots and waterfall graphs displaying tumor size trajectory over months of systemic therapy that doctors can share with patients.
High-resolution data flow architecture connecting point-of-care capture, diagnostic instruments, and national health registries.
A transparent 5-stage digital pathway standardizing patient care from initial requisition to longitudinal review.
Oncologist and radiologist define baseline target lesions (e.g. Target 1: RLL Lung 32mm, Target 2: Liver Segment IV 24mm; Baseline SLD = 56mm).
At 3-month scan, same lesions are re-measured (Target 1: 18mm, Target 2: 12mm; New SLD = 30mm).
Software calculates: (30 - 56) / 56 = -46.4% reduction from baseline.
System auto-categorizes response as Partial Response (PR) and checks for any new suspicious lesions.
Oncologist confirms therapeutic efficacy, continues current regimen, and updates patient's longitudinal EMR profile.
Medical365 Tumor Tracking conforms to international RECIST 1.1 guidelines, iRECIST criteria for immunotherapy clinical trials, and ICMR oncology standards.
All anatomical measurement logs, radiologic calibrations, and response categories are encrypted under AES-256 compliant with the DPDP Act 2023. Tumor response registries link seamlessly with ABDM digital health lockers.
See how automated digital intelligence transforms efficiency, reduces diagnostic turnaround times, and protects clinical revenue.
| Feature / Requirement | Conventional Manual Practice | Medical365 EMR Solution ★ |
|---|---|---|
| Response Evaluation |
✕ Manual Method: Subjective narrative notes like 'tumor seems smaller' |
✓ Medical365 Solution: Standardized RECIST 1.1 calculating exact percentage change in SLD |
| Target Lesion Consistency |
✕ Manual Method: Different lesions measured on different visits; comparing apples to oranges |
✓ Medical365 Solution: Permanent anatomical tagging tracking the identical baseline lesions over time |
| Nadir Calculation |
✕ Manual Method: Physicians forget smallest historical size; easily missing subtle progression |
✓ Medical365 Solution: Automated nadir tracking calculating ≥20% increase from lowest point |
| Immunotherapy Pseudoprogression |
✕ Manual Method: Immunotherapy stopped prematurely due to initial tumor flare/swelling |
✓ Medical365 Solution: iRECIST criteria distinguishing unconfirmed (iUPD) vs confirmed (iCPD) progression |
| Patient Visualization |
✕ Manual Method: Abstract millimeter numbers confusing to anxious patients and families |
✓ Medical365 Solution: Intuitive waterfall graphs and spider plots illustrating tumor shrinkage |
Seamless bidirectional data sharing across all hospital clinical departments and diagnostics.
Clinical, technical, and regulatory answers for hospital directors and medical specialists.
Target lesions are measurable lesions (longest diameter ≥10 mm on CT, or lymph nodes with short axis ≥15 mm) up to a maximum of 5 lesions total. Non-target lesions are all other disease sites (e.g. bone metastases, pleural effusion, small nodules), which are tracked qualitatively.
Using iRECIST guidelines, an initial increase in tumor size is classified as immune Unconfirmed Progressive Disease (iUPD). Treatment continues, and a repeat scan at 4 to 8 weeks confirms whether the tumor is growing (iCPD) or demonstrating delayed shrinkage (iPR/iSD).
Yes. Radiologists can use digital calipers on the integrated Medical365 DICOM viewer to measure lesion diameters; measurements auto-populate the oncology RECIST tracking flowsheet.
The appearance of any unequivocal new malignant lesion on follow-up imaging automatically triggers an overall assessment of Progressive Disease (PD), regardless of the measurements of existing target lesions.
Yes. The module supports the Lugano classification for lymphomas, incorporating 5-point Deauville scores on FDG-PET/CT to define complete metabolic response (CMR) and partial metabolic response (PMR).
Yes. Comprehensive RECIST 1.1 audit sheets—including baseline measurements, interim scans, percentage changes, and attached DICOM key frames—can be exported to PDF or Excel for clinical trials and academic audits.
